Stocks-Prognosis.com
Search on StockPrognosis.com
To search on the site stockprognosis.com enter the name of the ticker, company name, or search phrase
Sections of the site



Vertex Pharmaceuticals Poised for Strong Growth with Suzetrigine, says Jim Cramer

February 02, 2025
After analyzing the prospects for Vertex Pharmaceuticals Incorporated (VRTX) and its promising drug Suzetrigine, stock market expert Jim Cramer commented on its potential for growth. Cramer acknowledged that Suzetrigine had been viewed as the "drug of the future" for Vertex, but he expressed caution regarding the upside potential of the stock. However, Cramer highlighted the underlying strength of Vertex as a company and stated that investors should seek professional advice from Stocks Prognosis to make an informed decision on the stock's future movement.
If you want to leave a comment, then you need Login or Register





Other data for VRTX

Related data

VRTXJuly 9, 2025VERTEX PHARMACEUTICALS INCORPORATED Hits Price Target with 8.54% Profit Margin  ~1 min.

VERTEX PHARMACEUTICALS INCORPORATED (VRTX) recently achieved its price target forecast, generating an 8.54% profit margin for investors....

VRTXJuly 9, 2025VERTEX PHARMACEUTICALS INCORPORATED Stock Hits Forecast Target with 7.36% Profit  ~1 min.

VERTEX PHARMACEUTICALS INCORPORATED (VRTX) stock successfully achieved the price target forecast set by QuantWave, a leading automated forecasting platform, with a profitable outcome of 7.36%....

VRTXJuly 9, 2025VERTEX PHARMACEUTICALS INCORPORATED Stock Reaches Price Target Forecast with 8.02% Profit  ~1 min.

VERTEX PHARMACEUTICALS INCORPORATED stock successfully reached the price target forecast set by QuantWave on July 9, 2025....

VRTXJuly 9, 2025VERTEX PHARMACEUTICALS INCORPORATED Hits Forecast Target with 8.37% Profit: A Success Story for QuantWave  ~1 min.

VERTEX PHARMACEUTICALS INCORPORATED (VRTX) recently achieved the forecast price target set by QuantWave, resulting in a profit of 8.37% for investors who followed the long prediction signal....

VRTXJuly 9, 2025VERTEX PHARMACEUTICALS INCORPORATED Stock Hits Forecasted Price Target with 8.64% Profit  ~1 min.

VERTEX PHARMACEUTICALS INCORPORATED (VRTX) stock successfully reached the forecasted price target set by QuantWave on 2025-06-20, with a predicted long direction. The stock was valued at 440....

VRTXJuly 9, 2025VERTEX PHARMACEUTICALS INCORPORATED Hits QuantWave Forecast Target with 7.59% Profit  ~2 min.

VERTEX PHARMACEUTICALS INCORPORATED (VRTX) has successfully reached the forecast price target set by QuantWave on June 30, 2025....

VRTXJuly 9, 2025Vertex Pharmaceuticals Incorporated Hits Price Target Forecast with 7.44% Profit  ~1 min.

Vertex Pharmaceuticals Incorporated (VRTX) has successfully achieved the price target forecast set by QuantWave, resulting in a profit of 7.44%....

VRTXJune 8, 2025Vertex Pharmaceuticals Incorporated VRTX Reports Positive Outcomes from CFTR Modulator Studies  ~1 min.

Vertex Pharmaceuticals Incorporated (VRTX) recently announced positive outcomes from their CFTR modulator studies, showing promising results in the treatment of cystic fibrosis....

VRTXMay 31, 2025Vertex Pharmaceuticals Incorporated Continues to Impress Investors With Groundbreaking Research  ~1 min.

Vertex Pharmaceuticals Incorporated has been making waves in the pharmaceutical industry with its innovative research and development efforts....

VRTXMay 12, 2025Vertex Pharmaceuticals Incorporated VRTX Surged On a Recovery in Investor Sentiment  ~1 min.

Vertex Pharmaceuticals Incorporated (VRTX) experienced a surge in its stock price due to a recovery in investor sentiment....

VRTXFebruary 4, 2025Vertex Pharmaceuticals Stock Jumps as Non-Opioid Painkiller Gets FDA Approval  ~2 min.

Vertex Pharmaceuticals Incorporated (VRTX) saw a significant increase in its stock price after the FDA approved its non-opioid painkiller drug....

VRTXJanuary 31, 2025Jim Cramer on Vertex Pharmaceuticals' Suzetrigine: Limited Upside Potential for Drug of the Future  ~2 min.

Vertex Pharmaceuticals Incorporated, a renowned biopharmaceutical company, recently faced critical analysis from Jim Cramer, a prominent financial expert....

VRTXFebruary 3, 2025Vertex Pharmaceuticals Incorporated VRTX to Unveil Q4 2024 Financial Results on February 10  ~2 min.

Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) has announced that it will be revealing its fourth quarter and full-year 2024 financial results on February 10....

HBAR-USDMarch 16, 2025US SEC Acknowledges Grayscales Hedera ETF Filing What Next  ~2 min.

The US Securities and Exchange Commission (SEC) has recently acknowledged Grayscales' filing for a Hedera ETF....

BMYDecember 24, 2024Bristol-Myers Squibb Company BMY Announces Exciting Developments in Cancer Research  ~2 min.

Bristol-Myers Squibb Company BMY, a leading pharmaceutical company, has recently made significant advancements in cancer research that are capturing the attention of investors and medical professionals alike....